In acute lymphoblastic leukemia (ALL), there is a high prevalence of aberrant RASSF6 promoter methylation, and its DNA methylation status has the potential to serve as a biomarker for assessing MRD levels in ALL patients (43). The gene discussed is RASSF6; the disease is acute lymphoblastic leukemia.